UNILEVER PLC (UL)
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-09-09
$62.49-1.65%
Close 2026-09-09 · 1-day change
NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-09-09
Intact: The reason to own it still holds.
Unilever grows sales by expanding health supplements in Europe and Asia. It invests in brands like Liquid IV and Supply6. The $4 billion Thorne deal could boost earnings. The company is not losing money and has steady sales near $52 billion.
Unilever faces trust issues from a $66 billion food deal dispute. Valuation concerns may limit stock gains. Growth could slow if acquisitions fail or markets weaken.
The market has no clear consensus on growth or fair value. Our view sees potential from supplements and partnerships that may not be fully priced in.
Breaks if: no meaningful growth in Liquid IV European sales in 12 months
Breaks if: EPS falls below $3.00 in FY26
Thorne deal fails or is abandoned within 12 months
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is in the Consumer Staples sector, which is generally seen as stable but currently faces challenges. The thesis is in a state of insufficient clarity due to recent financial performance and a lack of strong momentum.
The market appears to have low expectations for UL, as indicated by the low fragility tier. There is no current indication of significant risk priced into the stock, but the muted price reaction suggests that investors are cautious.
Fundamentally, UL has a moderate risk profile with a near-term miss probability of 31%. The company has been experiencing consecutive earnings misses, which raises concerns about its ability to meet expectations in the near future.
The long-term thesis hinges on several factors. If inflation reaccelerates or if sector leaders like PG, CL, and EL continue to perform well, UL could benefit. Conversely, if these leaders start to miss expectations, UL may face additional challenges.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. Unilever's recent partnership with McCormick enhances growth prospects. The company also plans continued investment in India for future growth.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: annual revenue falls below $50 billion in FY26
In the next 1 to 3 years, UL's performance will depend heavily on broader sector dynamics and its ability to improve earnings. Not investment advice.